Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (74)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Orelabrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Orelabrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Pacritinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Pacritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Panobinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Panobinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Pexmetinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Pexmetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
PF-06821497 (EZH2 Inhibitor) |
EZH2 Inhibitor | Hematologic | ||
|
Molecule
PF-06821497 (EZH2 Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
||||
Pirtobrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Pirtobrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Ponatinib |
BCR-ABL Tyrosine Kinase Inhibitor | Hematologic (Leukemia) | ||
|
Molecule
Ponatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
||||
Pracinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Pracinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Quisinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Quisinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Quizartinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Quizartinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Radotinib |
BCR-ABL Tyrosine Kinase Inhibitor | Hematologic (Leukemia) | ||
|
Molecule
Radotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
||||
Resminostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Resminostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
OrelabrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
PacritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
PanobinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
PexmetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
PF-06821497 (EZH2 Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
|
PirtobrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
PonatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
|
PracinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
QuisinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
QuizartinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
RadotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
|
ResminostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|